Abstract

Guardian Pharmacy Services, Inc. will report fiscal results on March 11, 2026 Post Market, with investors focused on revenue momentum, margin resilience, and EPS trajectory into the current quarter.

Market Forecast

Consensus and company-indicated projections for the current quarter point to revenue of $389.15 million, implying year-over-year growth of 16.94%, with EBIT estimated at $22.50 million and adjusted EPS at $0.25; year-over-year growth rates are forecast at 38.60% for EBIT and 51.52% for EPS. Gross margin and net margin guidance were not explicitly provided for this quarter, though last quarter’s profitability metrics serve as a baseline comparison. The main business continues to be Pharmaceutical And Medical Products, where demand trends and execution remain central to near-term performance. Within this mix, Pharmaceutical And Medical Products is also positioned as the leading potential growth contributor given its scale and revenue trajectory.

Last Quarter Review

In the most recent quarter, Guardian Pharmacy Services, Inc. delivered revenue of $377.43 million, a gross profit margin of 19.80%, GAAP net profit attributable to the parent company of $9.82 million, a net profit margin of 2.60%, and adjusted EPS of $0.15, with revenue rising 20.05% year over year and EPS up 107.50% year over year. A notable highlight was the sequential improvement in profitability, with net profit rising quarter on quarter by 8.73%, alongside outperformance versus revenue estimates. The main business, Pharmaceutical And Medical Products, generated $377.43 million in revenue; the YoY growth rate for the segment matched overall company growth last quarter, underscoring broad-based expansion in core operations.

Current Quarter Outlook (with major analytical insights)

Core pharmacy distribution and services

Revenue is guided to $389.15 million, suggesting sustained demand momentum as the company leans on prescription volume growth and contract wins. Margin durability is likely the central variable for investor reaction given last quarter’s 19.80% gross margin and 2.60% net margin baseline; with EBIT projected to grow 38.60% year over year, operating leverage is expected to improve if product mix and procurement efficiencies persist. Watch for working capital discipline and potential pricing normalization in key payor relationships that could influence revenue recognition and cost of goods sold dynamics.

EBIT and EPS trajectory

The EBIT estimate of $22.50 million aligns with an acceleration narrative relative to top-line growth, implying incremental margin expansion on a year-over-year basis. Adjusted EPS is forecast at $0.25, a 51.52% year-over-year increase, which embeds assumptions around stable gross margin performance and contained SG&A growth. Sensitivities include generic deflation cycles, reimbursement rate resets, and any transitory cost pressures in logistics or labor that could narrow the expected uplift.

Revenue cadence and volume drivers

The step-up from last quarter’s $377.43 million to an estimated $389.15 million reflects continued throughput in the main distribution channel and potential seasonal uplift. Volume indicators in long-term care and specialty-adjacent flows typically provide incremental contribution, though mix shifts can influence gross margin. Against a strong prior-year base, the 16.94% year-over-year revenue growth outlook will likely be parsed for sustainability into subsequent quarters, particularly if pricing tailwinds moderate.

Main business momentum and competitive posture

Pharmaceutical And Medical Products accounted for all reported revenue last quarter and remains the primary growth engine. Execution around supplier relationships and inventory turn will be important for sustaining last quarter’s 19.80% gross margin while capturing share where service-level reliability differentiates. Competitive intensity may show up through contract pricing and service fees, making scale and procurement advantages critical to protecting EBIT progression.

Key stock-price swing factors this quarter

- Profitability mix: If operating costs scale below revenue, the forecasted EPS uplift to $0.25 should be attainable, reinforcing the improving return profile. Any drift in gross margin below the historical baseline could compress EBIT and weigh on sentiment. - Cash conversion: Investors are likely to focus on cash flow consistency given expanding volumes; any working-capital build from higher receivables or inventory could be interpreted as a caution signal. - Guidance quality: Commentary around demand visibility, contract pipeline, and pricing environment will influence multiple expansion or compression more than the headline revenue result.

Analyst Opinions

The majority of recently published institutional takes skew positive, emphasizing the constructive setup for year-over-year growth in revenue and operating earnings alongside improving EPS leverage. Analysts highlighting the 16.94% revenue growth outlook and a 38.60% EBIT increase argue that steady gross margin execution around last quarter’s 19.80% baseline could validate an expansion in operating margin, supporting the path to the projected $0.25 EPS. Bullish commentary notes that last quarter’s performance beat revenue expectations and delivered a 107.50% year-over-year rise in adjusted EPS to $0.15, indicating that operational efficiency initiatives are gaining traction and may carry into the current quarter. From a risk standpoint, positive views acknowledge reimbursement and generic price dynamics as variables, but contend that procurement scale and contract visibility provide a buffer. Overall, the preponderance of coverage expects Guardian Pharmacy Services, Inc. to meet or slightly exceed the current quarter’s top-line and EPS forecasts, with the stock’s near-term reaction hinging on margin color and qualitative guidance around demand durability.